Manufactured Object – Page 17

WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift

8 months ago talkbio0Tagged asset, Biological Factors, BIOSECURE, Dundalk, Facility (object), Ireland, Merck, regulatory, Sales - occupational activity, strategic shift, Vaccines, WuXi

WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act

Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal

8 months ago talkbio0Tagged Biological Factors, Facility (object), Ireland, Merck, pharmaceutical manufacturing, Vaccines, WuXi

Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing

2024 FDA Drug Approvals: Small Companies Make Significant Impact

8 months ago talkbio0Tagged 2024, Drug Industry, regulatory, United States Food and Drug Administration

FDA drug approvals 2024, small biotech companies, pharmaceutical industry, new drug approvals, regulatory updates.

Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution

8 months ago talkbio0Tagged Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Pharmacy facility, shortage, United States Food and Drug Administration, Zepbound

Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound

Carecode Revolutionizes Brazilian Healthcare with AI-Powered Customer Service, Secures $4.3M Funding

8 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Automation, brazilian, Carecode, Customer, Health care facility, Services

Carecode, AI, Healthcare, Customer Service, Automation, Funding, Brazilian Healthcare

FDA Imposes Import Restrictions on 11 Viatris Products from Indian Facility Due to Regulatory Violations

9 months ago talkbio0Tagged Facility (object), Import, pharmaceutical manufacturing, Regulatory Violations, restrictions, United States Food and Drug Administration, Viatris

Viatris, FDA, Import Restrictions, India Facility, Regulatory Violations, Pharmaceutical Manufacturing

FDA Approves ALYFTREK, a Next-Generation CFTR Modulator for Cystic Fibrosis Treatment

9 months ago talkbio0Tagged ALYFTREK, Approved, CFTR, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Modulator Device, once-daily, United States Food and Drug Administration

ALYFTREK, cystic fibrosis, CFTR modulator, FDA approval, once-daily treatment, Vertex Pharmaceuticals

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

Healthcare Sector Winners and Losers in the 2024 Government Funding Bill

9 months ago talkbio0Tagged Government, Health care facility, hospital-at-home programs, Legislation, Medicaid, Medicare, pay, Payments, Physicians, shutdown, Symmetrical dyschromatosis of extremities, Telemedicine

Healthcare funding, government shutdown, telehealth, Medicare payments, Medicaid DSH, hospital-at-home programs, physician pay cuts, healthcare legislation.

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

9 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology